Mapping mutations that escape antibodies against COVID-19 suggests prior mapping incomplete

January 25, 2021

A new approach to mapping viral mutations that "escape" leading clinical antibodies has revealed mutations in the SARS-CoV-2 virus that allow it to evade treatments, including a single amino-acid mutation that fully escapes Regeneron's antibody cocktail. These maps, say the authors, demonstrate that prior characterization of escape mutations was incomplete. They will also help to enable immediate interpretation of the effects of the mutations cataloged by viral genomic surveillance, say the authors. Several antibodies are in use or under development as therapies to treat COVID-19. As new SARS-CoV-2 variants emerge, it is important to predict whether they will remain susceptible to antibody treatment. Most leading anti-SARS-CoV-2 antibodies target the viral receptor-binding domain (RBD), which facilitates binding to the ACE2 receptor on host cells. Tyler Starr and colleagues recently developed a scanning method to map how mutations to the RBD affect its recognition by antibodies. Here, Starr and colleagues leveraged this approach to show how mutations to SARS-CoV-2's RBD affect binding by the antibodies in the REGN-COV2 cocktail and by Eli Lilly's antibody LY-CoV016. The authors focused on mutations to the SARS-CoV-2 RBD that do not strongly disrupt binding to the host receptor (ACE-2), to map how these mutations impact binding to the three anti-SARS-CoV-2 antibodies. The maps identified mutations that escape antibody binding, including, surprisingly, a single mutation that escapes both antibodies in the Regeneron antibody cocktail. To determine if the escape maps could inform analysis of viral evolution in infected humans, the authors examined deep sequencing data from a persistently infected patient who was treated with REGN-COV2 at day 145 after diagnosis with COVID-19. The analysis identified resistance mutations that arose in this patient. Three of the four escape mutations identified by Starr and team had not been identified in Regeneron's viral cell-culture selections, say the authors, illustrating an advantage of complete maps as used here. The complete maps also permitted the researchers to assess what escape mutations are already present among circulating SARS-CoV-2. After examining all human-derived SARS-CoV-2 sequences available as of 11 January 2021, they report a substantial number of RBD mutations that escaped one or more of the antibodies are in circulation.

American Association for the Advancement of Science

Related Antibodies Articles from Brightsurf:

Scientist develops new way to test for COVID-19 antibodies
New research details how a cell-free test rapidly detects COVID-19 neutralizing antibodies and could aid in vaccine testing and drug discovery efforts.

Mussels connect antibodies to treat cancer
POSTECH research team develops innovative local anticancer immunotherapy technology using mussel protein.

For an effective COVID vaccine, look beyond antibodies to T-cells
Most vaccine developers are aiming solely for a robust antibody response against the SARS-CoV-2 virus, despite evidence that antibodies are not the body's primary protective response to infection by coronaviruses, says Marc Hellerstein of UC Berkeley.

Children can have COVID-19 antibodies and virus in their system simultaneously
With many questions remaining around how children spread COVID-19, Children's National Hospital researchers set out to improve the understanding of how long it takes pediatric patients with the virus to clear it from their systems, and at what point they start to make antibodies that work against the coronavirus.

The behavior of therapeutic antibodies in immunotherapy
Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells.

Re-engineering antibodies for COVID-19
Catholic University of America researcher uses 'in silico' analysis to fast-track passive immunity

Seroprevalence of antibodies to SARS-CoV-2 in 10 US sites
This study estimates how common SARS-CoV-2 antibodies are in convenience samples from 10 geographic sites in the United States.

Neutralizing antibodies in the battle against COVID-19
An important line of defense against SARS-CoV-2 is the formation of neutralizing antibodies.

Three new studies identify neutralizing antibodies against SARS-CoV-2
A trio of papers describes several newly discovered human antibodies that target the SARS-CoV-2 virus, isolated from survivors of SARS-CoV-2 and SARS-CoV infection.

More effective human antibodies possible with chicken cells
Antibodies for potential use as medicines can be made rapidly in chicken cells grown in laboratories.

Read More: Antibodies News and Antibodies Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to